A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength in healthy adults

Robert W Morton,1 Kevin T Murphy,1 Sean R McKellar,1 Brad J Schoenfeld,2 Menno Henselmans,3 Eric Helms,4 Alan A Aragon,5 Michaela C Devries,6 Laura Banfield,7 James W Krieger,8 Stuart M Phillips1

ABSTRACT

Objective We performed a systematic review, meta-analysis and meta-regression to determine if dietary protein supplementation augments resistance exercise training (RET)-induced gains in muscle mass and strength.

Data sources A systematic search of Medline, Embase, CINAHL and SportDiscus.

Eligibility criteria Only randomised controlled trials with RET ≥6 weeks in duration and dietary protein supplementation.

Design Random-effects meta-analyses and meta-regressions with four a priori determined covariates. Two-phase break point analysis was used to determine the relationship between total protein intake and changes in fat-free mass (FFM).

Results Data from 49 studies with 1863 participants showed that dietary protein supplementation significantly (all p<0.05) increased changes (means ±SD) in muscle mass (2.49±2.17 kg (0.64, 4.33)), fat-free mass (0.30±0.30 kg (0.09, 0.52)) and mid-femur cross-sectional area (CSA; 7.2±3.1 µm² (0.20, 14.30)) during periods of prolonged RET. The impact of protein supplementation on gains in FFM was reduced with increasing age (−0.01±0.01 kg/day, p=0.002) and was more effective in resistance-trained individuals (0.75±0.40 kg/day, p=0.03). Protein supplementation beyond total protein intakes of 1.62 g/kg/day resulted in no further RET-induced gains in FFM.

Summary/conclusion Dietary protein supplementation significantly enhanced changes in muscle strength and size during prolonged RET in healthy adults. Increasing age reduces and training experience increases the efficacy of protein supplementation during RET. With protein supplementation, protein intakes at amounts greater than ~1.6 g/kg/day do not further contribute RET-induced gains in FFM.

INTRODUCTION

Resistance exercise training (RET) in combination with dietary protein supplementation is a common practice, in athletes and recreational exercisers alike, with the aim of enhancing RET-induced gains in muscle mass and strength. Recognised as a potent antiquesarcopenic stimulus, protein supplementation has also been advocated for ageing persons participating in RET. Despite a large volume of work in this area, narrative reviews and even meta-analyses yield conflicting results as to the actual effectiveness of protein supplementation to enhance RET-mediated gains in muscle mass and strength. This lack of agreement on the efficacy of protein supplementation is likely due to the use of divergent study inclusion criteria and inclusion of subjects with differing: ages, training statuses, total protein intakes, protein sources and protein doses. Thus, an evidence-based answer to the main question of the efficacy of protein supplementation, while previously reported, now appears to be controversial.

We conducted a meta-analysis that was more inclusive in nature than previous meta-analyses to provide a broad, systematic and evidence-based assessment on whether protein supplementation can augment changes in relevant RET outcomes. We used meta-regression to evaluate the impact of important potentially mediating covariates that were decided a priori to the meta-analysis. The present meta-analysis includes more than double the number of studies and participants than the largest published comprehensive meta-analysis on protein supplementation during RET to date.

We also undertook an additional rational, mechanism-based analysis that had the aim of answering the following question: is there a protein intake beyond which protein supplementation ceases to provide a measurable benefit in increasing muscle mass during RET? To answer this question, we recognised that the process of muscle protein synthesis (MPS), as the primary determinant of muscle growth12 we theorised that the effect of daily protein intake on RET-induced changes in muscle mass would show a dose-responsive relationship but that this would ultimately plateau.

METHODS

Inclusion criteria Any randomised controlled trials (RCTs) that combined a RET and protein supplement intervention were considered for this meta-analysis. Trials had to be at least six weeks in duration,
participants had to be performing RET at least twice per week, and at least one group had to be given a protein supplement that was not co-ingested with other potentially hypertrophic agents (e.g., creatine, β-HMB, or testosterone-enhancing compounds). Only trials with humans who were healthy and not energy-restricted were accepted. Manuscripts had to be original research (not a review or conference abstract) and be written in English.

**Search strategy**
A systematic search of the literature was conducted (LB) in Medline, Embase, CINAHL and SportDiscus, current to January 2017 (see online supplementary appendix 1). As appropriate, a combination of keywords and subject headings was used for the following concepts: protein supplementation and resistance training or muscle strength. The original search yielded 3056 studies. Any overlooked trials were identified by consulting other reviews and meta-analyses on the subject and were added in manually (17 studies). After deduplication and screening for inclusion criteria, 155 articles were independently read/reviewed by three authors (RWM, KTM and SRM). A total of 49 RCTs were selected for inclusion in this meta-analysis (figure 1).

**Data extraction**
Predetermined relevant variables from each included study were gathered independently by three investigators (RWM, KTM and SRM). Relevant variables included those regarding the study design, details of the RET intervention, participant characteristics, protein supplement information, placebo/control information, performance outcomes, body composition outcomes and any other notable information (e.g., sources of bias/conflict of interest). Where data were not presented in table or text and authors could not be reached, data were extracted using WebPlotDigitizer (Web Plot Digitizer, V.3.11. Texas, USA: Ankit Rohatgi, 2017) or calculated from baseline values and/or percentage change. Where there were any discrepancies between the three reviewers the manuscripts were revisited by all reviewers (RWM, KTM and SRM) and agreed on by discussion. We also conducted a post hoc reassessment of 10 randomly selected studies and
compared the extracted results. Coder drift was <10% in all cases for each investigator and inter-rater (RWM, KTM and SRM) reliability was excellent (>95%).

A total of 58 different body composition and 66 performance outcomes were extracted from the final 49 studies. Primary outcomes were limited and amalgamated to include two different performance outcomes and four different body composition outcomes based on those most commonly reported in the 49 RCTs. Performance outcomes were: one-repetition-maximum strength (1RM; measured by any 1RM strength test) and maximum voluntary contraction (MVC; measured by both isokinetic and/or isometric contractions using a dynamometer with any muscle group/action). Body anthropometric and composition outcomes included: total body mass (TBM; measured by any scale); fat-free mass (FFM) and bone-free mass (or lean mass if FFM was not available); FFM; measured by dual-energy X-ray absorptiometry (DXA), hydrodensitometry, or whole-body air plethysmography (BodPod); fat mass (FM; measured by DXA, hydrodensitometry and/or BodPod); muscle fibre cross-sectional area (CSA; measured in any fibre subtype (I, IIa, and/or IIx) obtained from either vastus lateralis and/or latissimus dorsi biopsies using microscopy); and mid-femur whole muscle CSA (mid-femur CSA, measured by MRI and/or CT).

**Data syntheses**

When data were reported in different units (eg, pounds vs kilograms) the data were converted to metric units. In all analyses the comparator group received an identical RET intervention but was non-supplemented or placebo-supplemented. If a study included a protein-supplemented group, a non-supplemented control group and a placebo-supplemented control group that were all part of the RET intervention, the protein-supplemented and placebo-supplemented groups were retrieved. If a study had multiple time points, only the preintervention and postintervention outcomes were retrieved. Where the change in SD (ΔSD) was not reported, the correlation coefficient (corr) for each primary outcome was calculated according to the Cochrane Handbook for Systematic Reviews of Interventions:

\[
\text{corr} = \frac{\text{SD}_{\text{pre}}^2 + \text{SD}_{\text{post}}^2 - \text{SD}_{\text{change}}^2}{2 \times \text{SD}_{\text{pre}} \times \text{SD}_{\text{post}}}
\]

and the ΔSD was then calculated as:

\[
\Delta \text{SD} = \sqrt{(\text{SD}_{\text{pre}}^2 + \text{SD}_{\text{post}}^2 - 2 \times \text{corr} \times \text{SD}_{\text{pre}} \times \text{SD}_{\text{post}}}).
\]

The change in mean (ΔMean) and ΔSD were calculated for each condition and uploaded to RevMan (Review Manager (RevMan), V.5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014). Where studies had more than one protein-supplemented group (eg, soy and whey), measure of MVC (eg, isokinetic and/ or isometric) or measure of 1RM (eg, bench press and leg press) the ΔMean and ΔSD were independently calculated and later combined, unless otherwise stated, using the RevMan calculator (Review Manager (RevMan), V.5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014).

**Meta-analyses**

Random-effects meta-analyses were performed in RevMan (Review Manager (RevMan), V.5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) on the change in each outcome. Effect sizes are presented as mean difference (MD) with means±SD and 95% CIs for 1RM, TBM, FFM, FM, fibre CSA and mid-femur CSA and as standardised mean difference (SMD) and 95% CIs for MVC because it had multiple outcomes presented on non-comparable scales (eg, N and Nm).

**Heterogeneity and risk of bias**

Heterogeneity was assessed by χ² and I² and significance was set at p<0.05. The internal validity of each study was determined by domain-based evaluation to quantify risk of bias for each study and was independently performed by three investigators (RWM, KTM and SRM). The data included in the meta-analyses were restricted to studies with less than three reported high or unclear risk domains (predominately due to reported conflicts of interest and lack of blinding investigators and/or participants; see online supplementary appendix 2)). Funnel plots were visually inspected to determine publication bias. Multiple sensitivity analyses were performed to determine if any of the results were influenced by the studies that were removed.

**Meta-regression**

In an effort to understand the sources of heterogeneity meta-regressions were performed on 1RM, FFM and fibre CSA because they were statistically significant, had considerable unexplained heterogeneity (I²) and had a sufficient number of studies (≥10). Meta-regression was used instead of subgroup analyses to allow for the use of continuous covariates and to allow for the inclusion of more than one covariate at a time. Four covariates were chosen a priori to be included in our meta-regression: baseline protein intake (g/kg/day), postexercise protein dose (g), chronological age and training status because there is evidence that training status has a high influence on protein intake, sex (male vs female), diet (dietary-supplement vs RET-supplement), whole-body RET (whole-body RET vs not whole-body RET) and RET supervision (supervised vs not supervised). Protein supplement source was limited to soy and whey because there were few study groups that were provided either a casein (n=32)65 or pea (n=12)66 protein supplement exclusively.

**Subgroup analyses**

Subgroup analyses were performed in RevMan (Review Manager (RevMan), V.5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014). Subgroup analyses were
performed on changes in FFM and 1RM with training status (untrained vs trained) as the subgroup to generate forest plots and neatly present training status as a categorical variable. Subgroup analyses were also performed on changes in FFM with age categorised into subgroups (old (>45 years) and young (<45 years)) to be presented below for the interested reader.

Break point analysis
To investigate the influence of protein intake as a continuous variable on individual study arms (as opposed being limited to MDs between groups in a meta-regression) linear and segmental regressions on the change in FFM (measured by DXA) were plotted against daily and baseline protein intake. Linear and segmental regressions were performed using GraphPad Prism (V6, GraphPad Software, La Jolla, California, USA) to determine models of best fit as has been previously done in acute tracer trials measuring MPS.14 Where segmental regression was the preferred model the slope of the second line was set to zero to determine the break point (biphasic regression). Each group from each study that presented daily or baseline protein intake with changes in FFM from DXA was included. Significance was set at p<0.05 and data for the break point is presented as mean (95% CI).

RESULTS
Participant characteristics
Participant details and outcomes are presented elsewhere (see online supplementary table 1). A total of 49 studies from 17 countries met the inclusion criteria (figure 1). There were 10 studies in resistance-trained participants and 14 study groups in exclusively female participants. Publications ranged from 1962 to 2016. There was a total of 1863 participants (mean±SD; 35±20 years).

RET characteristics
The RET characteristics are also presented elsewhere (see online supplementary table 1). The RET interventions lasted from 6 weeks to 52 weeks (13±8 weeks) performing RET between 2 days and 5 days per week (3±1 days/week) with between 1 to 14 exercises per session (7±3 exercises/session), 1 to 12 sets per exercise (4±2 sets/exercise) and anywhere between 3 to 25 repetitions per set (9±4 repetitions/set). Four studies used just lower-body RET, two studies used just knee extensor RET, one study used elbow flexor RET only, and two studies used one lower-body and one upper-body exercise only.

Protein supplementation
Details regarding the experimental (protein supplementation) and control (placebo- or no-supplement) groups are presented elsewhere (see online supplementary table 2). A range of 4 g to 106 g of protein was supplemented per day to the protein group (36±30 g/day; young: 42±32 g/day; old: 20±18 g/day) with a range of 5 g to 44 g of protein supplemented postexercise on training days (24±11 g; young: 24±12 g; old: 23±10 g). Twenty-three conditions supplemented with whey protein, 3 with casein protein, 6 with soy protein, 1 with pea protein, 10 with milk or milk protein, 7 with whole food (eg, beef, yogurt, between-meal snack) and 13 with non-specific protein blends or blends containing multiple protein sources (eg, whey, casein, soy and egg). In 40 studies the participants consumed part or all of their daily protein supplement after their RET sessions. In 36 studies with 48 different conditions authors reported either total (g/day) or relative (g/kg/day or %kcal/day) daily protein intake preintervention and/or postintervention. There was an increase in daily protein intake in the protein group (mean±SD; range: 23±41 g/day; −25 g/day to 158 g/day; p=0.004) and no change in the control group (1±4 g/day; −17 g/day to 40 g/day; p=0.83) such that the change in daily protein intake was significantly greater in the protein group (p=0.01). Relative daily protein intake (g/kg/day) increased in the protein group (pre: 1.4±0.4, post: 1.8±0.7, Δ: 0.3±0.5 g/kg/day, p=0.002) and did not change in the control group (pre: 1.3±0.3, post: −0.02±0.1 g/kg/day, p=0.48) such that there was a greater change in the protein group (p<0.001). Daily energy intake (kcal/day) was gathered from 23 studies with 29 conditions and did not change with the prolonged RET and protein supplementation nor was it significantly different between the protein or control groups (Δ protein group: 50±293 kcal/day, Δ control group: 70±231 kcal/day, p=0.71).

Heterogeneity and risk of bias
Significant heterogeneity was found for changes in 1RM (I2=53.49, p=0.003) and fibre CSA (I2=30.97, p=0.0006). Nine studies were removed based on risk of bias17 18 23 25 50 63 (see online supplementary appendix 2) or publication bias assessment24 32 64 (see supplementary online figure 1). In particular, four studies were removed from 1RM, four from TBMs,17 18 23 64 three from FM,17 18 63 five from FFM,17 18 24 63 64 three from MVCS,23 26 30 and one from fibre CSA.50

Sensitivity analyses
Sensitivity analysis was performed with the nine high-risk studies mentioned above included in the outcomes they were removed from to determine if their removal changed any of the results. The inclusion of those studies did not influence the difference in means or significance in 1RM, TBMs, FFM or mid-femur CSA; however, when Mitchell et al26 was included in the fibre CSA assessment the effect of protein supplementation (310 µm2 (51, 570), p=0.02) was eliminated (153 µm2 (−137, 443), p=0.30). This is likely due to the small number of studies that included muscle biopsies but may warrant caution when interpreting the effect of protein supplementation on changes fibre CSA during RET. In no instance did fixed-effect meta-analysis deliver a different magnitude of effect or significance compared with random-effect meta-analysis.

Meta-analyses
Protein supplementation during prolonged RET significantly improved gains in 1RM strength (MD: 2.49 kg (0.64, 4.33), p=0.01; figure 2) but had no effect on MVC (SMD: 0.04 (−0.09, 0.16), p=0.54). Protein supplementation did not have a significant effect on changes in TBMs (MD: 0.11 kg (−0.23, 0.46), p=0.52) but improved changes in FFM (MD: 0.30 kg (0.09, 0.52), p=0.007; figure 3), FM (MD: −0.41 kg (−0.70, −0.13), p=0.005), fibre CSA (MD: 310 µm2 (51, 570), p=0.02; see online supplementary figure 2: panel A) and mid-femur CSA (MD: 7.2 mm2 (0.20, 14.30), p=0.04; see online supplementary figure 2: panel B) during prolonged RET.

Meta-regression
The results from the full model meta-regressions are presented in table 1. When combined, baseline protein intake, protein dose, age and training status did not explain any of the variance in the changes in 1RM (15 studies, 1216 subjects, p=0.77) or FFM (15 studies, 642 participants, p=0.12). There were insufficient observations (<10) when all covariates were compared with the changes in fibre CSA.
Review

Univariate meta-regressions on changes in 1RM and FFM following prolonged RET are also presented in table 1. None of our covariates explained any of the heterogeneity of protein supplementation’s effect on changes in 1RM: baseline protein intake (21 studies, 814 participants, p=0.59), age (27 studies, 802 participants, p=0.78), training status (28 studies, 858 participants, p=0.40) and post-exercise protein dose (23 studies, 589 participants, p=0.13). In contrast, when the ability of protein supplementation to affect changes in FFM was evaluated with univariate meta-regressions, the postexercise protein dose was the only covariate that did not influence the efficacy of protein supplementation on changes in FFM was evaluated with univariate meta-regressions, the postexercise protein dose was the only covariate that did not influence the efficacy of protein supplementation on changes in FFM. There were no covariates that explained any of the variance in the change in fibre CSA: age (10 studies, 474 participants, $I^2=65\%$, Adj. $R^2=-3\%$, p=0.50), baseline protein intake (8 studies, 384 participants, $I^2=-44\%$, p=0.84), postexercise protein dose (10 studies, 270 participants, $I^2=77\%$, Adj. $R^2=-38\%$, p=0.92) and training status (11 studies, 586 participants, $I^2=71\%$, Adj. $R^2=-24\%$, p=0.94).

Additional univariate meta-regressions are presented in elsewhere (see online supplementary table 3). Only whether the RET was whole-body (27 studies, including only 4 studies that were not whole-body RET, $I^2=2\%$, Adj. $R^2=76\%$, p=0.01) or supervised (28 studies, $I^2=5\%$, Adj. $R^2=58\%$, p=0.047) explained part of the variance in the effectiveness of protein supplementation on changes in 1RM. No other covariates explained any of the variance associated with the efficacy of protein supplementation on changes in 1RM or FFM.

Figure 2 Forest plot of the results from a random-effects meta-analysis shown as mean difference with 95% CIs on one-repetition-maximum (1RM; kg) in untrained and trained participants. For each study, the circle represents the mean difference of the intervention effect with the horizontal line intersecting it as the lower and upper limits of the 95% CI. The size of each circle is indicative of the relative weight that study carried in the meta-analysis. The rhombi represent the weighted untrained, trained and total group’s mean difference. Total: 2.49 kg (0.64, 4.33), p=0.01, untrained: 0.99 kg (−0.27, 2.25), p=0.12 and trained: 4.27 kg (0.61, 7.94), p=0.02.
Break point analysis

Biphasic regression (42 study arms, 723 participants) explained more variation than a linear regression between the change in FFM and daily protein intake (break point $= 1.62$ (1.03, 2.20) g/kg/day, slope = 1.75, $R^2 = 0.19$, $df = 36$) and is presented as a segmental regression despite not being statistically significant ($p = 0.079$; figure 5). When plotting the change in FFM against baseline protein intake, linear regressions explained significantly more variance than biphasic regressions in both young (slope = $-1.54$ g/kg/day, $R^2 = 0.17$, $df = 34$) and old (slope = 0.16 g/kg/day, $R^2 = 0.04$, $df = 14$) participants with a statistically significant difference between

![Forest plot](image_url)

**Figure 3** Forest plot of the results from a random-effects meta-analysis shown as mean difference with 95% CIs on lean or fat-free mass (FFM; kg) in untrained and trained participants. For each study, the circle represents the mean difference of the intervention effect with the horizontal line intersecting it as the lower and upper limits of the 95% CI. The size of each circle represents the relative weight that study carried in the meta-analysis. The rhombi represent the weighted untrained, trained and total group’s mean difference. Total: 0.30 kg (0.09, 0.52) $p = 0.007$, untrained: 0.15 kg (−0.02, 0.31), $p = 0.08$ and trained: 1.05 kg (0.61, 1.50), $p < 0.0001$.

### Table 1: Meta-regression output

<table>
<thead>
<tr>
<th>Model</th>
<th>N</th>
<th>1RM (kg)</th>
<th>$\tau^2$</th>
<th>Adj. $R^2$</th>
<th>$I^2$</th>
<th>p Value</th>
<th>N</th>
<th>Coeff. (95% CI)</th>
<th>$\tau^2$</th>
<th>Adj. $R^2$</th>
<th>$I^2$</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>No covariates</td>
<td>28</td>
<td>2.49 (0.64 to 4.33)</td>
<td>6.05</td>
<td>33%</td>
<td>0.01</td>
<td>22</td>
<td>0.30 (0.09 to 0.52)</td>
<td>0.05</td>
<td>7%</td>
<td>&lt;0.01</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Univariate</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline protein intake</td>
<td>21</td>
<td>2.85 (-8.15 to 13.84)</td>
<td>7.82</td>
<td>1%</td>
<td>37%</td>
<td>0.59</td>
<td>27</td>
<td>0.64 (0.02 to 1.27)</td>
<td>0</td>
<td>100%</td>
<td>0%</td>
<td>0.045</td>
</tr>
<tr>
<td>Protein dose</td>
<td>23</td>
<td>0.13 (-0.04 to 0.31)</td>
<td>3.16</td>
<td>40%</td>
<td>0%</td>
<td>0.13</td>
<td>20</td>
<td>0.02 (-0.01 to 0.04)</td>
<td>0.09</td>
<td>0%</td>
<td>0%</td>
<td>0.25</td>
</tr>
<tr>
<td>Age</td>
<td>27</td>
<td>0.01 (-0.09 to 0.11)</td>
<td>6.51</td>
<td>-9%</td>
<td>34%</td>
<td>0.78</td>
<td>25</td>
<td>-0.01 (-0.02 to 0.00)</td>
<td>0</td>
<td>100%</td>
<td>0%</td>
<td>0.02</td>
</tr>
<tr>
<td>Training status</td>
<td>28</td>
<td>5.77 (-2.96 to 7.13)</td>
<td>5.77</td>
<td>5%</td>
<td>31%</td>
<td>0.40</td>
<td>26</td>
<td>0.75 (0.09 to 1.40)</td>
<td>0.03</td>
<td>49%</td>
<td>0%</td>
<td>0.03</td>
</tr>
<tr>
<td>All covariates</td>
<td>15</td>
<td>5.36</td>
<td>10%</td>
<td>0%</td>
<td>0.77</td>
<td>15</td>
<td>0</td>
<td>100%</td>
<td>0%</td>
<td>0.12</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline protein intake</td>
<td>15</td>
<td>6.40 (-11.62 to 24.42)</td>
<td>0.43</td>
<td>15</td>
<td>-57 (-2.50 to 1.37)</td>
<td>0.95</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Protein dose</td>
<td>15</td>
<td>0.05 (-0.78 to 0.88)</td>
<td>0.70</td>
<td>15</td>
<td>-0.01 (-0.07 to 0.06)</td>
<td>0.99</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>15</td>
<td>0.07 (-0.18 to 0.33)</td>
<td>0.23</td>
<td>15</td>
<td>-0.01 (-0.02 to 0.00)</td>
<td>0.19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Training status</td>
<td>15</td>
<td>-2.81 (-20.80 to 15.17)</td>
<td>0.63</td>
<td>15</td>
<td>1.19 (-1.34 to 2.19)</td>
<td>0.48</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
age groups (p=0.042; see online supplementary figure 3: panel D).

DISCUSSION
This is the largest meta-analysis on interventions including dietary protein supplementation with muscle and strength-related outcomes during prolonged RET to date. Our main finding was that dietary protein supplementation augmented RET-induced increases in 1RM strength (figure 2) and FFM (figure 3). For changes in FFM, dietary protein supplementation was more effective in resistance-trained individuals (table 1 and figure 3), less effective with increasing chronological age (table 1 and figure 4) and did not increase beyond total protein intakes of −1.6 g/kg/day (figure 5). Our data show dietary protein supplementation is both sufficient and necessary to optimise RET adaptations in muscle mass and strength.

Previous meta-analyses6–12 have reached varying conclusions when examining the impact of protein supplementation on changes in lean mass or FFM and 1RM strength during RET. The discrepancies are likely a consequence of differing study inclusion criteria. For example, previous meta-analyses have included only trained participants,8,10 only older adults,9,11 supplements containing more than just protein,10,11 only one source of protein,8,12 shorter RET interventions,10 frail/sarcopenic participants7,9,11 and/or participants who were energy-restricted.6,7,12 Previously, the largest comprehensive meta-analysis to date on protein supplementation during RET included 22 studies and 680 participants7 and did not increase beyond total protein intakes of −1.6 g/kg/day (figure 5). Our data show dietary protein supplementation augmented gains in FFM and strength with RET.

Strength
The average RET-induced increase, with all measures of 1RM included, was 27 kg (mean±SD; 27±22 kg12). Notably, dietary protein supplementation augmented the increase in 1RM strength by 2.49 kg (9%; figure 2; see online supplementary figure 4), which strongly suggests that the practice of RET is a far more potent stimulus for increasing muscle strength than the addition of dietary protein supplementation. None of our covariates (age, training status, postexercise protein dose or baseline protein intake) influenced the efficacy of protein supplementation on changes in 1RM strength. Improving performance of a specific task (eg, the 1RM of an exercise) is predominately determined by the practice of that task.71 Though protein supplementation may slightly augment changes in 1RM (~−9%), which may be important for those competing in powerlifting or weightlifting, it is pragmatic to advocate that if an increase in 1RM is the objective of an RET programme, a sufficient amount of work and practice at or around the 1RM is far more influential than protein supplementation.

Muscle mass
In addition to increasing changes in muscle strength, RET alone (≥6; 13±8 weeks) resulted in an increase in FFM (1.1±1.2 kg), an increase in fibre CSA (808±) and an increase in mid-femur CSA (52±30 mm²). Dietary protein supplementation augmented the increase in FFM by 0.30 kg (27%; see supplementary figure 2: panel A) and mid-femur CSA by 7.2 mm² (14%; see online supplementary figure 2: panel B). The postexercise protein dose did not affect the efficacy of protein supplementation on RET-induced changes in FFM whereas training status (positive), age (negative) and baseline protein intake (positive) did. Relative to untrained participants, resistance-trained participants have a smaller potential for muscle growth72 and an attenuated postexercise muscle protein turnover.73 As a result, we speculate that trained persons may have less ‘degrees of freedom’ to change with RET and therefore have a greater need for protein supplementation to see increases in muscle mass. Our thesis is supported by the observation of a more consistent impact of protein supplementation on gains in FFM in resistance-trained individuals than in novice trainees (figure 3).

Older individuals are anabolically resistant74 and require higher per-meal protein doses to achieve similar rates of MPS, the primary variable regulating changes in skeletal muscle mass,75 compared with younger participants.14 The average supplemental daily protein dose given to older participants was surprisingly low (20±18 g/day); thus, it is perhaps not surprising that we did not find that older individuals were responsive to protein supplementation (figure 4). Though age did not affect
the RET-induced change in fibre CSA, the negative effect age had on changes in FFM leads us to speculate that even though exercise sensitises muscle to the effect of protein ingestion, older persons have an increased need for higher protein intakes to optimally respond to this effect and see gains in FFM.13

It has been theorised that the increased deviation from normal protein intake (g/kg/day) will positively affect the RET-induced gains in FFM.13 Contrary to this thesis, we found that a higher prestudy protein intake actually resulted in a greater effect of protein supplementation on changes in FFM (table 1); however, this was likely driven by the lower mean baseline protein intake (old: 1.2±0.2 g/kg/day; young: 1.5±0.4 g/kg/day) and daily protein dose (old: 20±18 g/day, young: 42±32 g/day) in the studies that included older participants (see online supplementary figure 3; panel B and D). Indeed, a sensitivity analysis that did not include older (>45; 65±14 years) versus younger (<45; 24±4 years) individuals found that baseline protein intake had no effect on the efficacy of protein supplementation in young individuals (see online supplementary figure 3, panel C). In an unadjusted meta-regression analysis, a higher baseline protein intake in young individuals actually attenuated the change in FFM (see online supplementary figure 3, panel D).

A goal of this meta-analysis was to deliver evidence-based recommendations that could be readily translated. A crucial point is that even though the mean baseline protein intake for the 1863 participants was ~1.4 g protein/kg/day, which is 75% greater than the current US/Canadian recommended dietary allowance (RDA),14 an average supplementation of ~35 g protein/day still augmented RET-stimulated gain in FFM (figure 3) and 1RM strength (figure 2). Thus, consuming protein at the RDA of 0.8 g protein/kg/day appears insufficient for those who have the goal of gaining greater strength and FFM with RET. This conclusion is emphasised for older men65 and women70 75 76 wishing to obtain strength and gain lean mass with RET and protein supplementation.

A recent retrospective analysis showed a ‘breakpoint’ for the stimulation of MPS when ingesting an isolated protein source at 0.24 g protein/kg and 0.40 g protein/kg in younger and older participants, respectively.14 Given the observation of a dose-responsive relationship between protein intake and MPS62–85 and the fact that MPS is aligned with muscle hypertrophy,13 we elected to use an identical two-segment regression approach between total daily protein intake and changes in FFM (figure 5) as has been done for changes in protein dose and MPS.14 Here we provide significant insight (using 42 study arms including 723 young and old participants with protein intakes ranging from 0.9 g protein/kg/day to 2.4 g protein/kg/day) by reporting an unadjusted plateau in RET-induced gains in FFM at 1.62 g protein/kg/day (95%CI: 1.03 to 2.20). These results are largely in congruence with previous narrative reviews that comment on the optimal nutritional strategies to augment skeletal muscle adaptation during RET.7 86 Given that the CI of this estimate spanned from 1.03 to 2.20, it may be prudent to recommend ~2.2 g protein/kg/d for those seeking to maximise resistance training-induced gains in FFM. Though we acknowledge that there are limitations to this approach, we propose that these findings are based on reasonable evidence and theory and provide a pragmatic estimate with an incumbent error that the reader could take into consideration.

Although the present analysis provides important and novel data, there are limitations that we acknowledge. First, the lack of RET research in older individuals has led to inconclusive recommendations from previous meta-analyses specifically focusing on older individuals.7 65 Indeed, in this manuscript there were only 13 studies that met our inclusion criteria in older (>45 years) individuals and only six of those studies reported baseline protein intakes with changes in FFM. In addition, only four studies27 29 31 45 in older individuals had participants that consumed what we consider to be close to optimal total protein intake (~1.2 g/kg/day to 1.6 g/kg/ day) in non-exercising adults.86 Furthermore, only two studies23 30 in older individuals provided a postexercise supplemental protein dose that we consider to be close to optimal (~35–40 g) to stimulate FFM accretion in elderly individuals.27 Given that older adults require more protein per day,79 80 consume less protein per day79 80 and that dietary protein ingestion and RET are effective strategies to maintain muscle mass and function with age,87 future RET research should focus on using higher protein doses (or potentially higher leucine), larger sample sizes and longer interventions in ageing populations. Second, we included a variety of additional covariates into univariate meta-regressions to elucidate the variables that may modify whether protein supplementation affects RET-induced changes in muscle mass and strength. Such an approach is generally considered to be hypothesis generating. The only significant findings we found were that if the RET sessions were whole-body (adjusted R²=76%, p=0.01) or supervised (adjusted R²=58%, p=0.047), protein supplementation was more effective at augmenting changes in 1RM. No variable affected changes in FFM (see online supplementary table 3). Given the relatively small effect that protein supplementation has on changes in FFM and 1RM, clearly other variables as a component of RET programmes are of much greater importance. Our meta-analyses also only included studies with participants that were at or above their energy requirements, which may have omitted the significant impact protein has during periods of weight loss with RET.88 Lastly, we found that the postexercise protein dose did not affect the efficacy of protein supplementation on RET-induced changes in FFM. Our analysis, and those from others,6 leads us to conclude that the specifics of protein supplementation (eg, timing, postexercise protein dose or protein source) play a minor, if any, role in determining RET-induced gains in FFM and strength over a period of weeks. Instead, our results indicate that a daily protein intake of ~1.6 g/kg/day, separated into ~0.25 g/kg doses,14 is more influential on adaptive changes with RET, at least for younger individuals.

CONCLUSION

Dietary protein supplementation augments changes in muscle mass and strength during prolonged RET. Protein supplementation is sufficient at ~1.6 g/kg/day in healthy adults during RET. Based on limited data we observed no overtly apparent sex-based differences but acknowledge that far less work has been done in women than men. This analysis shows that dietary protein supplementation can be, if protein intake is less than 1.6 g protein/kg/day, both sufficient and necessary to optimise RET-induced changes in FFM and 1RM strength. However, performance of RET alone is the much more potent stimulus, accounting, at least according to this meta-analysis, for a substantially greater portion of the variance in the RET-induced gains in muscle mass and strength.

Acknowledgements SMP thanks the Canada Research Chairs, Canadian Institutes for Health Research, and the Natural Science and Engineering Research Council of Canada for their support during the completion of this work.

Contributors RW, BJS, MH, EH, AAA, MCD, JWK and SMP contributed to the conception and design of the study. RW, BJS, MH, EH, AAA, MCD, LB, JWK and SMP contributed to the development of the search strategy. LB conducted the systematic search. RW, KTM and SRM completed the acquisition of data. RW and SMP performed the data analysis. All authors assisted with the interpretation.
and license their derivative works on different terms, provided the original work is expressly granted.

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018; All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES
Review


Correction: A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength in healthy adults


Brad Schoenfeld declares that he served on the advisory board for Dymatize Nutrition, a manufacturer of sports supplements, at the time this paper was being written. He continues to serve on the advisory board.

Open access. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.